CREBBP and diffuse large B-cell lymphoma: In a cellular model of diffuse large B-cell lymphoma (DLBCL), the inhibition of HDAC3 rescues the aberrant epigenetic programming associated with CREBBP mutations, enhancing BCL6-mediated antigen presentation and the release of IFN-γ.